KRAS and familial pancreatic carcinoma: However, the activating point-mutation of the Kras oncogene on codon 12 (Exon 2) remains the major event (70–95% of PDAC cases: 71% of pancreatic cancer specimens in the COSMICS database harbour Kras mutations) [17,18,19].